GAMMA Investing
RXRX icon

GAMMA Investing’s Recursion Pharmaceuticals RXRX Stock Holding History

GAMMA Investing’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$17.4K Buy
4,209
+3,787
+897% +$12.8K ﹤0.01% 3032
2026
Q2 		$1.55K Sell
422
-312
-43% -$1.04K ﹤0.01% 3772
2026
Q1 		$2.25K Sell
734
-939
-56% -$3.63K ﹤0.01% 3636
2025
Q4 		$6.84K Buy
1,673
+1,422
+567% +$7.04K ﹤0.01% 3140
2025
Q3 		$1.23K Buy
251
+193
+333% +$1.01K ﹤0.01% 3571
2025
Q2 		$293 Sell
58
-7,166
-99% -$35.2K ﹤0.01% 3700
2025
Q1 		$38.2K Buy
7,224
+2,026
+39% +$14.8K ﹤0.01% 1984
2024
Q4 		$35.1K Buy
5,198
+4,948
+1,979% +$33.3K ﹤0.01% 1934
2024
Q3 		$1.65K Sell
250
-6,166
-96% -$44.2K ﹤0.01% 3126
2024
Q2 		$48.1K Buy
6,416
+6,036
+1,588% +$52.6K 0.01% 1218
2024
Q1 		$3.79K Buy
380
+130
+52% +$1.45K ﹤0.01% 2524
2023
Q4 		$2.35K Buy
+250
New +$1.78K ﹤0.01% 2528

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing's RXRX Position: Q3 2026 in Review

GAMMA Investing increased its Recursion Pharmaceuticals (RXRX) stake by 897% in Q3 2026, buying an estimated $12.8K and bringing the position to 4,209 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

GAMMA Investing first reported a position in RXRX in Q4 2023 and has held it in 12 quarters since. The position peaked at $48.1K in Q2 2024. 20 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • GAMMA Investing held 4,209 shares of Recursion Pharmaceuticals worth $17.4K as of Q3 2026.
  • GAMMA Investing bought 3,787 Recursion Pharmaceuticals shares in Q3 2026, an estimated $12.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3032 holding.
  • GAMMA Investing first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Recursion Pharmaceuticals position peaked at $48.1K in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.